Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX7353 Drug-Drug Interaction Study with Digoxin, Rosuvastatin, and Cyclosporine
NCT03136237Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Feb 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of berotralstat in hereditary angioedema (HAE) (3 cohorts), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve to the Last Measurable Concentration and 1 more. Started Feb 2017; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03136237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136237.